Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Interest Expenses (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Interest Expenses for 13 consecutive years, with $560000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Interest Expenses fell 48.1% to $560000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $2.7 million, a 40.96% decrease, with the full-year FY2025 number at $3.7 million, down 26.8% from a year prior.
  • Interest Expenses was $560000.0 for Q4 2025 at Aytu Biopharma, up from $516000.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $1.3 million in Q3 2023 to a low of $516000.0 in Q3 2025.
  • A 3-year average of $983800.0 and a median of $1.0 million in 2024 define the central range for Interest Expenses.
  • Peak YoY movement for Interest Expenses: fell 14.77% in 2024, then tumbled 48.1% in 2025.
  • Aytu Biopharma's Interest Expenses stood at $1.3 million in 2023, then dropped by 14.77% to $1.1 million in 2024, then tumbled by 48.1% to $560000.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Interest Expenses are $560000.0 (Q4 2025), $516000.0 (Q3 2025), and $730000.0 (Q2 2025).